Brii Biosciences (Brii Bio), a multi-national innovative therapies developer with operations in both China and the US, has raised $155 million in a Series C round of financing ahead of a potential listing in Hong Kong.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
